Women's Health

GLP-1 Weight-Loss Medication for Women Over 40: What the Evidence Shows

By the US Health Digest editorial team · July 24, 2026

Women were roughly three-quarters of the participants in the pivotal GLP-1 obesity trials, and the average participant in the landmark semaglutide trial was 46 years old — so the efficacy data does describe women in midlife. What it does not describe is menopause. The trials did not randomize by menopausal status, and the public results record for the semaglutide trial does not mention menopause at all. Much of what circulates about "GLP-1s and menopause" is inference layered on trials never designed to test it. Below: what is established, what is inferred, what is unknown.

What changes in midlife, and why weight management gets harder

The physiology here is better documented than the drug question. In a four-year longitudinal study of 156 initially premenopausal women, visceral abdominal fat increased significantly only in those who became postmenopausal, though all participants gained subcutaneous abdominal fat with age. In a calorimetry subset, the decline in sleeping energy expenditure was 1.5-fold greater in women who became postmenopausal, and fat oxidation fell 32% in that group but did not change in women who remained premenopausal (Lovejoy et al., International Journal of Obesity, 2008).

This is observational data — association and timing, not mechanism. But the pattern is consistent: the midlife difficulty women describe coincides with measurable shifts in where fat is stored and how much energy the body burns at rest.

What the trials do — and don't — tell us about women over 40

In STEP 1, adults with obesity taking semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks versus 2.4% on placebo, across 1,961 participants (Wilding et al., NEJM, 2021). The public results record shows 1,453 of those participants were female — 74.1% — with a mean age of 46 (ClinicalTrials.gov, NCT03548935). SURMOUNT-4, the tirzepatide maintenance trial, was 71% women (Aronne et al., JAMA, 2024).

So women were the evidence base. That is the strongest honest statement available. What does not follow: the STEP 1 registry record contains no mention of menopausal status — not as an eligibility criterion, not as a baseline characteristic, not as a subgroup. Participants were not randomized by menopausal stage, and menopause-specific outcomes were not prespecified. Any claim that a GLP-1 works differently in perimenopause is not answered by these trials in either direction.

Table sources: Jastreboff et al., NEJM, 2022 and Aronne et al., NEJM, 2025. See also Wegovy vs. Zepbound and semaglutide results for women.

Muscle and lean mass: the question women over 40 ask most

A 2026 review in the European Journal of Clinical Investigation concluded that GLP-1 receptor agonists reduce fat mass more than lean body mass, with a modest absolute decline in lean body mass and functional measures that appear preserved — no consistent deterioration in strength or physical function. It suggests the benefit runs through muscle quality — microvascular recruitment, mitochondrial efficiency, reduced intramuscular fat — rather than muscle growth (De Girolamo et al., 2026).

"Fat falls more than lean" is accurate, and easy to over-read. The DXA substudy within STEP 1 is worth seeing in full: over 68 weeks, participants on semaglutide lost an average of 9.3 kg of fat mass and 5.8 kg of lean body mass, with lean mass rising 3.4 percentage points as a share of total body mass (NCT03548935 results). Both readings are true at once: the proportion improved, and several kilograms of lean tissue still went. That substudy covered 83 participants on semaglutide and 39 on placebo — a small fraction of the trial, carrying wide uncertainty.

For a woman already in the window where bone density is declining for reasons unrelated to any medication, "the ratio improved" is not the same as "nothing was lost."

Protein and resistance training: what the evidence supports

The EJCI review's own recommendations are progressive resistance training, adequate high-quality protein, and periodic monitoring of body composition and physical performance, particularly in higher-risk patients (De Girolamo et al., 2026).

On protein, the most-cited numbers come from the PROT-AGE Study Group: an average daily intake of 1.0 to 1.2 g of protein per kg of body weight for people over 65, at least 1.2 g/kg/day for those who exercise, and 1.2–1.5 g/kg/day during acute or chronic illness — with an explicit exception for severe kidney disease, where intake may need to be limited (Bauer et al., JAMDA, 2013). Note the population: that guidance was written for adults over 65, not for women in their forties on a GLP-1. It is the closest established benchmark, not a direct match — which is why we do not publish a single target for women on a GLP-1, and why the number worth following is the one your prescriber or a registered dietitian sets from your labs and history.

What clinicians commonly advise during GLP-1 treatment

• Prioritizing protein at each meal, because appetite suppression shrinks total intake and protein is the component most often displaced — see protein-first eating on a GLP-1.
• Resistance training that progresses over time in load or repetitions rather than staying static, matching the "progressive" qualifier in the review.
• Periodic measurement of body composition and physical performance, not scale weight alone.
• Raising kidney function with a prescriber before increasing protein intake, per the PROT-AGE exception.

None of this is a plan for any individual. Protein targets and exercise programming interact with kidney function, cardiac history, joint disease, and current medications — which is why they belong in an appointment, not an article.

Bone health in midlife

Midlife bone loss is well characterized independent of any medication. In a multiethnic cohort of 862 women, bone mineral density loss began about a year before the final menstrual period and decelerated — but did not stop — two years after it. Lumbar spine BMD fell 10.6% over ten years, 7.38% of that in the transmenopause window; femoral neck loss was 9.1% overall and 5.8% during the transition (Greendale et al., JBMR, 2012).

What we did not find is trial-grade evidence on how GLP-1 treatment interacts with that window. We are not aware of a randomized trial powered to answer whether GLP-1-associated weight loss affects bone density differently in perimenopausal or postmenopausal women. For a woman with a fracture history, family history of osteoporosis, or a low bone density result, that is a question for a clinician, not for this page.

Stopping, and what regain looks like

SURMOUNT-4 is the clearest available answer. After a 36-week open-label lead-in in which participants lost a mean of 20.9% of body weight, they were randomized to continue tirzepatide or switch to placebo for 52 weeks. Those who continued lost a further 5.5%; those switched to placebo regained 14.0% (Aronne et al., JAMA, 2024). This trial did not report results by menopausal status either. More in what happens when you stop a GLP-1.

Gastrointestinal side effects drove discontinuation in 4.5% of the semaglutide group in STEP 1 versus 0.8% on placebo (NEJM, 2021); see GLP-1 side effects in women. And perimenopausal women can still conceive, including with irregular cycles — see GLP-1s, pregnancy and fertility.

What we don't know yet

Also unestablished, though widely asserted: any advantage from combining hormone therapy with a GLP-1, and any menopause-specific weight-loss figure. We looked for primary sources for both and did not find them. Where you see such figures, the useful question is which trial produced them.

One thing that is established: the FDA has documented problems with unapproved and compounded GLP-1 products — 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, plus dosing errors requiring hospitalization, unapproved salt forms, and products sold "for research purposes only" with dosing instructions attached (FDA).

Questions for your prescriber

1. Given my age and cycle history, does menopausal stage change your approach — and is that trial data or clinical judgment?
2. How will we monitor lean mass and physical function, not just scale weight? Will body composition be measured, and how often?
3. What protein intake is appropriate for me, and does my kidney function affect that answer?
4. Do I have bone density risk factors worth assessing before or during treatment?
5. What is the plan if I stop — for cost, coverage, or side effects — given what SURMOUNT-4 showed about regain?
6. How do my current medications and any hormone therapy interact with this drug?
7. Is this an FDA-approved product or a compounded one, and why?
8. What would make you change or stop it, and what should I report between visits?

Roughly 12% of US adults say they have ever used a GLP-1 drug and 6% currently use one, per a nationally representative poll of 1,479 adults (KFF, May 2024). Use has outrun menopause-specific evidence. That gap is the honest headline.